Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
But the former is paying a fraction of what Merck shelled out for raludotatug.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
